159 related articles for article (PubMed ID: 27775699)
1. SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance.
Sheets JN; Iwanicki M; Liu JF; Howitt BE; Hirsch MS; Gubbels JA; Drapkin R; Egland KA
Oncogenesis; 2016 Oct; 5(10):e264. PubMed ID: 27775699
[TBL] [Abstract][Full Text] [Related]
2.
Sheets JN; Patrick ME; Egland KA
Oncotarget; 2020 Jun; 11(24):2290-2301. PubMed ID: 32595828
[TBL] [Abstract][Full Text] [Related]
3. Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells.
Lager TW; Roetman JJ; Kunkel J; Thacker M; Sheets JN; Egland KA; Miles CM; Larson MK; Gubbels JAA
Platelets; 2018 Dec; 29(8):834-837. PubMed ID: 30335544
[TBL] [Abstract][Full Text] [Related]
4. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer.
Xu Y; Miao C; Jin C; Qiu C; Li Y; Sun X; Gao M; Lu N; Kong B
Exp Cell Res; 2018 Feb; 363(2):160-170. PubMed ID: 29305171
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of endometrial mesenchymal marker SUSD2 causes cell senescence and cell death in endometrial carcinoma cells.
Zhang S; Zeng N; Alowayed N; Singh Y; Cheng A; Lang F; Salker MS
PLoS One; 2017; 12(8):e0183681. PubMed ID: 28841682
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of sushi domain containing 2 is associated with progression of non-small cell lung cancer.
Cai C; Shi R; Gao Y; Zeng J; Wei M; Wang H; Zheng W; Ma W
Oncol Lett; 2015 Dec; 10(6):3619-3624. PubMed ID: 26788179
[TBL] [Abstract][Full Text] [Related]
7. Multiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesis.
Watson AP; Evans RL; Egland KA
Mol Cancer Res; 2013 Jan; 11(1):74-85. PubMed ID: 23131994
[TBL] [Abstract][Full Text] [Related]
8. In vivo tumor growth of high-grade serous ovarian cancer cell lines.
Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE
Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922
[TBL] [Abstract][Full Text] [Related]
9. Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers.
Sadlecki P; Jóźwicki J; Antosik P; Grabiec M
Tumour Biol; 2018 Jun; 40(6):1010428318784807. PubMed ID: 29952249
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of Sushi Domain Containing 2 correlates to progressive features in patients with hepatocellular carcinoma.
Liu XR; Cai CX; Luo LM; Zheng WL; Shi R; Zeng J; Xu YQ; Wei M; Ma WL
Cancer Cell Int; 2016; 16():15. PubMed ID: 26933386
[TBL] [Abstract][Full Text] [Related]
11. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.
Matte I; Legault CM; Garde-Granger P; Laplante C; Bessette P; Rancourt C; Piché A
Clin Exp Metastasis; 2016 Dec; 33(8):839-852. PubMed ID: 27612856
[TBL] [Abstract][Full Text] [Related]
12. Beyond genomics: critical evaluation of cell line utility for ovarian cancer research.
Elias KM; Emori MM; Papp E; MacDuffie E; Konecny GE; Velculescu VE; Drapkin R
Gynecol Oncol; 2015 Oct; 139(1):97-103. PubMed ID: 26321251
[TBL] [Abstract][Full Text] [Related]
13. Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma.
Guo W; Shao F; Sun S; Song P; Guo L; Xue X; Zhang G; Zhang H; Gao Y; Qiu B; Tan F; Gao S; He J
J Cancer; 2020; 11(7):1648-1656. PubMed ID: 32194777
[TBL] [Abstract][Full Text] [Related]
14. SUSD2 promotes tumor-associated macrophage recruitment by increasing levels of MCP-1 in breast cancer.
Hultgren EM; Patrick ME; Evans RL; Stoos CT; Egland KA
PLoS One; 2017; 12(5):e0177089. PubMed ID: 28475599
[TBL] [Abstract][Full Text] [Related]
15. A Unique Pattern of Mesothelial-Mesenchymal Transition Induced in the Normal Peritoneal Mesothelium by High-Grade Serous Ovarian Cancer.
Pakuła M; Uruski P; Niklas A; Woźniak A; Szpurek D; Tykarski A; Mikuła-Pietrasik J; Książek K
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31086083
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
Haley J; Tomar S; Pulliam N; Xiong S; Perkins SM; Karpf AR; Mitra S; Nephew KP; Mitra AK
Oncotarget; 2016 May; 7(22):32810-20. PubMed ID: 27147568
[TBL] [Abstract][Full Text] [Related]
17. Snail knockdown reverses stemness and inhibits tumour growth in ovarian cancer.
Hojo N; Huisken AL; Wang H; Chirshev E; Kim NS; Nguyen SM; Campos H; Glackin CA; Ioffe YJ; Unternaehrer JJ
Sci Rep; 2018 Jun; 8(1):8704. PubMed ID: 29880891
[TBL] [Abstract][Full Text] [Related]
18. Mesothelial vitronectin stimulates migration of ovarian cancer cells.
Heyman L; Leroy-Dudal J; Fernandes J; Seyer D; Dutoit S; Carreiras F
Cell Biol Int; 2010 Apr; 34(5):493-502. PubMed ID: 20121701
[TBL] [Abstract][Full Text] [Related]
19. SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer.
Cheng Y; Wang X; Wang P; Li T; Hu F; Liu Q; Yang F; Wang J; Xu T; Han W
Tumour Biol; 2016 Jul; 37(7):9919-30. PubMed ID: 26815503
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting ULK1 kinase decreases autophagy and cell viability in high-grade serous ovarian cancer spheroids.
Singha B; Laski J; Ramos Valdés Y; Liu E; DiMattia GE; Shepherd TG
Am J Cancer Res; 2020; 10(5):1384-1399. PubMed ID: 32509386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
